Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
13 05 2021
Historique:
received: 07 04 2020
revised: 14 12 2020
accepted: 15 03 2021
pubmed: 14 4 2021
medline: 22 12 2021
entrez: 13 4 2021
Statut: ppublish

Résumé

Receptor tyrosine kinase (RTK)-mediated activation of downstream effector pathways such as the RAS GTPase/MAP kinase (MAPK) signaling cascade is thought to occur exclusively from lipid membrane compartments in mammalian cells. Here, we uncover a membraneless, protein granule-based subcellular structure that can organize RTK/RAS/MAPK signaling in cancer. Chimeric (fusion) oncoproteins involving certain RTKs including ALK and RET undergo de novo higher-order assembly into membraneless cytoplasmic protein granules that actively signal. These pathogenic biomolecular condensates locally concentrate the RAS activating complex GRB2/SOS1 and activate RAS in a lipid membrane-independent manner. RTK protein granule formation is critical for oncogenic RAS/MAPK signaling output in these cells. We identify a set of protein granule components and establish structural rules that define the formation of membraneless protein granules by RTK oncoproteins. Our findings reveal membraneless, higher-order cytoplasmic protein assembly as a distinct subcellular platform for organizing oncogenic RTK and RAS signaling.

Identifiants

pubmed: 33848463
pii: S0092-8674(21)00362-7
doi: 10.1016/j.cell.2021.03.031
pmc: PMC8127962
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
EML4-ALK fusion protein, human 0
GAB1 protein, human 0
GRB2 Adaptor Protein 0
GRB2 protein, human 0
Oncogene Proteins, Fusion 0
SOS1 Protein 0
SOS1 protein, human 0
ras Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2649-2664.e18

Subventions

Organisme : NCI NIH HHS
ID : U01 CA217882
Pays : United States
Organisme : NIGMS NIH HHS
ID : R00 GM126136
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA210444
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224081
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM131641
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213775
Pays : United States
Organisme : NIGMS NIH HHS
ID : R21 GM129652
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM124334
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA128583
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204302
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007618
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA126792
Pays : United States
Organisme : NIGMS NIH HHS
ID : K99 GM126136
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211052
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231300
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA179512
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169338
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of interest T.G.B. is an advisor to Array Biopharma/Pfizer, Revolution Medicines, Relay Therapeutics, Rain Therapeutics, Novartis, AstraZeneca, Takeda, Springworks, and Jazz Pharmaceuticals and receives research funding from Novartis, Revolution Medicines, and Strategia.

Références

Cell. 2015 Aug 27;162(5):1066-77
pubmed: 26317470
Mol Cell Biol. 1993 Dec;13(12):7587-95
pubmed: 8246975
Mol Biol Cell. 2008 Oct;19(10):4154-66
pubmed: 18653466
Proc Natl Acad Sci U S A. 1990 Apr;87(8):3042-6
pubmed: 2183224
Cell Signal. 2015 Oct;27(10):1963-76
pubmed: 26163824
Cell. 2017 Sep 21;171(1):163-178.e19
pubmed: 28844694
Nat Rev Cancer. 2017 Oct 25;17(11):637-658
pubmed: 29068003
Cell. 2019 Jan 24;176(3):419-434
pubmed: 30682370
Nat Med. 2015 Sep;21(9):1038-47
pubmed: 26301689
Curr Protoc Mol Biol. 2010 Oct;Chapter 14:Unit14.20
pubmed: 20890901
Nat Methods. 2016 Jul;13(7):557-62
pubmed: 27240257
Cancers (Basel). 2017 Sep 05;9(9):
pubmed: 28872581
Nat Commun. 2017 Aug 29;8(1):370
pubmed: 28851864
Science. 2001 Dec 7;294(5549):2179-81
pubmed: 11679632
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15500-5
pubmed: 16223883
EMBO Rep. 2012 Aug;13(8):733-40
pubmed: 22732841
Trends Mol Med. 2017 Jan;23(1):59-79
pubmed: 27988109
Cell. 2016 Jan 28;164(3):487-98
pubmed: 26777405
Science. 2016 Apr 29;352(6285):595-9
pubmed: 27056844
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Nat Rev Mol Cell Biol. 2017 May;18(5):285-298
pubmed: 28225081
Mol Cancer Res. 2018 Nov;16(11):1724-1736
pubmed: 30002191
Traffic. 2012 Aug;13(8):1106-12
pubmed: 22531034
J Cell Mol Med. 2012 Feb;16(2):237-48
pubmed: 21854543
Science. 2019 Mar 8;363(6431):1098-1103
pubmed: 30846600
J Biol Methods. 2014;1(2):
pubmed: 25606571
J Immunol. 2010 Sep 15;185(6):3536-43
pubmed: 20713885
J Cell Biol. 2005 Jul 18;170(2):261-72
pubmed: 16027222
Cancer Discov. 2018 Jul;8(7):797-799
pubmed: 29967074
Clin Cancer Res. 2017 Apr 15;23(8):1988-1997
pubmed: 27683183
Cell. 1992 Aug 7;70(3):431-42
pubmed: 1322798
Science. 2017 Sep 22;357(6357):
pubmed: 28935776
J Cell Biol. 2003 Jan 20;160(2):165-70
pubmed: 12527752
Cell. 2015 Sep 24;163(1):123-33
pubmed: 26406374
J Cell Biol. 2016 Aug 15;214(4):445-58
pubmed: 27502489
Cell. 2017 Jun 1;169(6):1066-1077.e10
pubmed: 28575670
EMBO J. 1994 Sep 1;13(17):4011-21
pubmed: 7521298
Clin Cancer Res. 2015 Apr 15;21(8):1819-27
pubmed: 25878363
Biochem J. 2015 May 1;467(3):529-36
pubmed: 25740311
Cell Rep. 2019 Dec 17;29(12):4053-4068.e6
pubmed: 31851933
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1533-1542
pubmed: 31871156
Curr Biol. 1995 Jun 1;5(6):635-42
pubmed: 7552174
Nature. 1993 May 6;363(6424):83-5
pubmed: 8479540
Nature. 1984 Aug 16-22;310(5978):583-6
pubmed: 6087162
Mol Cancer. 2018 Feb 19;17(1):58
pubmed: 29455648
N Engl J Med. 2005 Jul 14;353(2):133-44
pubmed: 16014883
EMBO J. 1996 Jun 17;15(12):3016-27
pubmed: 8670803
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
EMBO J. 1994 Mar 1;13(5):1073-83
pubmed: 8131741
Thyroid. 2019 Nov;29(11):1704-1707
pubmed: 31650892
Nature. 1993 May 6;363(6424):85-8
pubmed: 8479541
Mol Cell. 2018 Jan 18;69(2):334-346.e4
pubmed: 29307513
Methods Mol Biol. 2014;1120:285-305
pubmed: 24470033
Proc Natl Acad Sci U S A. 1986 Feb;83(4):952-6
pubmed: 3513168
Elife. 2015 Aug 04;4:e06807
pubmed: 26238190
Mol Cell. 2017 Feb 2;65(3):416-431.e6
pubmed: 28157504

Auteurs

Asmin Tulpule (A)

Division of Pediatric Hematology/Oncology, UCSF, San Francisco, CA 94143, USA.

Juan Guan (J)

Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA; Department of Physics, University of Florida, Gainesville, FL 32611, USA.

Dana S Neel (DS)

Department of Medicine, Division of Hematology and Oncology, UCSF, San Francisco, CA 94143, USA.

Hannah R Allegakoen (HR)

Division of Pediatric Hematology/Oncology, UCSF, San Francisco, CA 94143, USA.

Yone Phar Lin (YP)

Division of Pediatric Hematology/Oncology, UCSF, San Francisco, CA 94143, USA.

David Brown (D)

Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA.

Yu-Ting Chou (YT)

Department of Medicine, Division of Hematology and Oncology, UCSF, San Francisco, CA 94143, USA.

Ann Heslin (A)

Division of Pediatric Hematology/Oncology, UCSF, San Francisco, CA 94143, USA.

Nilanjana Chatterjee (N)

Department of Medicine, Division of Hematology and Oncology, UCSF, San Francisco, CA 94143, USA.

Shriya Perati (S)

Division of Pediatric Hematology/Oncology, UCSF, San Francisco, CA 94143, USA.

Shruti Menon (S)

Division of Pediatric Hematology/Oncology, UCSF, San Francisco, CA 94143, USA.

Tan A Nguyen (TA)

Department of Pathology and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA 94143, USA.

Jayanta Debnath (J)

Department of Pathology and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA 94143, USA.

Alejandro D Ramirez (AD)

Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA.

Xiaoyu Shi (X)

Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA.

Bin Yang (B)

Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA.

Siyu Feng (S)

UC Berkeley-UCSF Graduate Program in Bioengineering, UCSF, San Francisco, CA 94143, USA.

Suraj Makhija (S)

Department of Pathology and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA 94143, USA.

Bo Huang (B)

Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA 94143, USA; Department of Biochemistry and Biophysics, UCSF, San Francisco, CA 94143, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. Electronic address: bo.huang@ucsf.edu.

Trever G Bivona (TG)

Department of Medicine, Division of Hematology and Oncology, UCSF, San Francisco, CA 94143, USA. Electronic address: trever.bivona@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH